ReviewDrugs2025
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy.
Sha Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ReviewDrugs2025
Sha Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.